Breast Cancer Coverage from Every Angle

Steven J. O’Day, MD, on Activating Innate Immunity in Triple-Negative Breast Cancer and Other Tumors

Posted: Sunday, May 10, 2020

Steven J. O’Day, MD, of the John Wayne Cancer Institute, discusses the rationale for using Imprime PGG (a novel innate immune activator) to trigger immunity and possibly enhance response to pembrolizumab in patients with metastatic triple-negative breast cancer. He also explores the treatment’s potential in other tumor types.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.